Literature DB >> 23385795

Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.

Catherine E Oldenburg1, Prajna Lalitha, Muthiah Srinivasan, Palanisamy Manikandan, M Jayahar Bharathi, Revathi Rajaraman, Meenakshi Ravindran, Jeena Mascarenhas, Natalie Nardone, Kathryn J Ray, David V Glidden, Nisha R Acharya, Thomas M Lietman.   

Abstract

PURPOSE: Bacterial keratitis is a sight-threatening infection of the cornea that is one of the leading causes of blindness globally. In this report, we analyze the role of moxifloxacin susceptibility in the relationship between causative organisms and clinical outcome in bacteria keratitis.
METHODS: A mediation analysis is used to assess the role of moxifloxacin susceptibility in the relationship between causative organisms and clinical outcome in bacterial keratitis using data collected in a randomized, controlled trial.
RESULTS: In the Steroids for Corneal Ulcers Trial (SCUT), 500 corneal infections were treated with topical moxifloxacin. The outcome of 3-week best spectacle-corrected visual acuity was significantly associated with an organism (Streptococcus pneumoniae, Pseudomonas aeruginosa, etc., P = 0.008). An indirect effects mediation model suggests that MIC accounted for approximately 13% (95% confidence interval, 3%-24%, P = 0.015) of the effect of the organism on 3-week visual acuity.
CONCLUSIONS: Moxifloxacin mediates the relationship between causative organisms and clinical outcome in bacterial keratitis, and is likely on the causal pathway between the organism and outcome. (ClinicalTrials.gov number, NCT00324168.).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385795      PMCID: PMC4136376          DOI: 10.1167/iovs.12-11246

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  23 in total

1.  Susceptibility testing and clinical outcome in fungal keratitis.

Authors:  Brett L Shapiro; Prajna Lalitha; Allison R Loh; Annette W Fothergill; Namperumalsamy V Prajna; Muthiah Srinivasan; Amit Kabra; Jaya Chidambaram; Nisha R Acharya; Thomas M Lietman
Journal:  Br J Ophthalmol       Date:  2010-03       Impact factor: 4.638

2.  Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Authors:  Prajna Lalitha; Muthiah Srinivasan; P Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Vicky Cevallos; Catherine E Oldenburg; Kathryn J Ray; Christine M Toutain-Kidd; David V Glidden; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2012-03-23       Impact factor: 9.079

3.  Causative organisms in microbial keratitis, their sensitivity pattern and treatment outcome in western Nepal.

Authors:  K Dhakhwa; M K Sharma; S Bajimaya; A K Dwivedi; S Rai
Journal:  Nepal J Ophthalmol       Date:  2012 Jan-Jun

4.  Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis.

Authors:  A K Leck; P A Thomas; M Hagan; J Kaliamurthy; E Ackuaku; M John; M J Newman; F S Codjoe; J A Opintan; C M Kalavathy; V Essuman; C A N Jesudasan; G J Johnson
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

5.  Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.

Authors:  Prajna Lalitha; N Venkatesh Prajna; Catherine E Oldenburg; Muthiah Srinivasan; Tiruvengada Krishnan; Jeena Mascarenhas; C M Vaitilingam; Stephen D McLeod; Michael E Zegans; Travis C Porco; Nisha R Acharya; Thomas M Lietman
Journal:  Cornea       Date:  2012-06       Impact factor: 2.651

Review 6.  Geographic variations in microbial keratitis: an analysis of the peer-reviewed literature.

Authors:  Ameet Shah; Arun Sachdev; David Coggon; Parwez Hossain
Journal:  Br J Ophthalmol       Date:  2011-04-08       Impact factor: 4.638

7.  Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Authors:  Aiyin Chen; Lalitha Prajna; Muthiah Srinivasan; Rajendran Mahalakshmi; John P Whitcher; Stephen McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2008-01-22       Impact factor: 5.258

8.  Aetiological diagnosis of microbial keratitis in South India - a study of 1618 cases.

Authors:  M J Bharathi; R Ramakrishnan; S Vasu; R Palaniappan
Journal:  Indian J Med Microbiol       Date:  2002 Jan-Mar       Impact factor: 0.985

9.  Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis.

Authors:  Stephen Kaye; Stephen Tuft; Timothy Neal; Derek Tole; John Leeming; Francisco Figueiredo; Malcolm Armstrong; Peter McDonnell; Andrew Tullo; Christopher Parry
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-13       Impact factor: 4.799

10.  Risk factors and causative organisms in microbial keratitis.

Authors:  Matthew Green; Andrew Apel; Fiona Stapleton
Journal:  Cornea       Date:  2008-01       Impact factor: 2.651

View more
  12 in total

1.  Topical Corticosteroids in the Management of Bacterial Keratitis.

Authors:  Sonal S Tuli
Journal:  Curr Ophthalmol Rep       Date:  2013-12

Review 2.  Update on the Management of Infectious Keratitis.

Authors:  Ariana Austin; Tom Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2017-09-21       Impact factor: 12.079

Review 3.  Pattern recognition receptors in microbial keratitis.

Authors:  M-A Taube; M del Mar Cendra; A Elsahn; M Christodoulides; P Hossain
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

4.  The Utility of Repeat Culture in Fungal Corneal Ulcer Management: A Secondary Analysis of the MUTT-I Randomized Clinical Trial.

Authors:  Kathryn J Ray; Prajna Lalitha; N Venkatesh Prajna; Revathi Rajaraman; Tiruvengada Krishnan; Muthiah Srinivasan; Peter Ryg; Stephen McLeod; Nisha R Acharya; Thomas M Lietman; Jennifer Rose-Nussbaumer
Journal:  Am J Ophthalmol       Date:  2017-04-04       Impact factor: 5.258

Review 5.  Topical corticosteroids as adjunctive therapy for bacterial keratitis.

Authors:  Samantha Herretes; Xue Wang; Johann M G Reyes
Journal:  Cochrane Database Syst Rev       Date:  2014-10-16

6.  Emodin ameliorates lipopolysaccharides-induced corneal inflammation in rats.

Authors:  Guo-Ling Chen; Jing-Jing Zhang; Xin Kao; Lu-Wan Wei; Zhi-Yu Liu
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

7.  Corneal infection in Shandong peninsula of China: a 10-year retrospective study on 578 cases.

Authors:  Xiao-Jing Pan; Tao Jiang; Hai Zhu; Peng-Peng Liu; Zhan-Yu Zhou; Alexander J Mao
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

8.  Anti-inflammatory effect of emodin on lipopolysaccharide-induced keratitis in Wistar rats.

Authors:  Guoling Chen; Jingjing Zhang; Han Zhang; Ying Xiao; Xin Kao; Yanli Liu; Zhiyu Liu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 9.  Role of steroids in the treatment of bacterial keratitis.

Authors:  Sotiria Palioura; Christopher R Henry; Guillermo Amescua; Eduardo C Alfonso
Journal:  Clin Ophthalmol       Date:  2016-01-27

10.  Rho Kinase Type 1 (ROCK1) Promotes Lipopolysaccharide-induced Inflammation in Corneal Epithelial Cells by Activating Toll-Like Receptor 4 (TLR4)-Mediated Signaling.

Authors:  Jianying Gong; Linan Guan; Pei Tian; Chao Li; Yi Zhang
Journal:  Med Sci Monit       Date:  2018-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.